Corrigendum: Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer (British Journal of Cancer (2016) 115 (789-796) DOI: 10.1038/bjc.2016.271)

Authors :: Dalgleish AG
Stebbing J
Adamson DJ
Arif SS
Bidoli P
Chang D
Cheeseman S
Diaz-Beveridge R
Fernandez-Martos C
Glynne-Jones R
Granetto C
Massuti B
McAdam K
McDermott R
Martín AJ
Papamichael D
Pazo-Cid R
Vieitez JM
Zaniboni A
Carroll KJ
Wagle S
Gaya A
Mudan SS.
Dalgleish, A
Stebbing, J
Adamson, D
Arif, S
Bidoli, P
Chang, D
Cheeseman, S
Diaz-Beveridge, R
Fernandez-Martos, C
Glynne-Jones, R
Granetto, C
Massuti, B
Mcadam, K
Mcdermott, R
Martín, A
Papamichael, D
Pazo-Cid, R
Vieitez, J
Zaniboni, A
Carroll, K
Wagle, S
Gaya, A
Mudan, S
Publication Year :: 2016
Publisher :: Nature Publishing Group, 2016.
Abstract: Upon publication of the above paper in the British Journal of Cancer, the authors identified an error in one of their affiliations. The authors would like to apologise for this mistake. The correct affiliation for Andrés J Munoz Martín is 'Medical Oncology Service, Hospital General Universitario Gregorio Maranón, Madrid, Spain.'

Tools